Follow us

NH TherAguix NEWS

NH TherAguix announces the release of a new clinical batch for it’s drug AGuIX manufactured by CARBOGEN AMCIS

MEYLAN, France, BUBENDORF, Switzerland (November 3rd, 2021) – NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.

View Event

NH TherAguix reporte son projet d’introduction en bourse sur le marché Euronext Growth à Paris

Grenoble (France), 13 octobre 2021 – L’offre proposée a suscité un intérêt immédiat de la part des investisseurs, conscients du potentiel du candidat-médicament AGuIX® et des besoins médicaux non-satisfaits auquel ce dernier répond. Toutefois, au vu du contexte boursier particulièrement volatil, NH TherAguix a décidé de reporter son projet d’introduction en bourse dans l’attente de conditions de marché plus favorables.

View Press Release

 

€13M A series funding

NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance – Grenoble/Lyon/Paris (France) – 11 April 2019

View Press Release

Categories

 

Archives